Development and Validation of a Novel LC-MS/MS Method for the Simultaneous Determination of Abemaciclib, Palbociclib, Ribociclib, Anastrozole, Letrozole, and Fulvestrant in Plasma Samples: A Prerequisite for Personalized Breast Cancer Treatment

Palbociclib, ribociclib and abemaciclib were recently approved as chemotherapeutic agents and are currently in the post-marketing surveillance phase. They are used in combination with aromatase inhibitors anastrozole and letrozole or antiestrogen fulvestrant for HR+, HER2− breast cancer treatment. H...

Descripción completa

Detalles Bibliográficos
Autores principales: Turković, Lu, Bočkor, Luka, Ekpenyong, Oscar, Silovski, Tajana, Lovrić, Mila, Crnković, Slaven, Nigović, Biljana, Sertić, Miranda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9147789/
https://www.ncbi.nlm.nih.gov/pubmed/35631440
http://dx.doi.org/10.3390/ph15050614

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9147789/
https://www.ncbi.nlm.nih.gov/pubmed/35631440
http://dx.doi.org/10.3390/ph15050614

Ejemplares similares